Effect of TachoSil on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

Trial Profile

Effect of TachoSil on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Fibrinogen/thrombin (Primary)
  • Indications Bladder cancer; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016, as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 11 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top